HPV Infection And Cervical Cancer
Published on Mar 16 2010, in the categories: Causes, diagnosis, Facts, HPV, Stages of disease, Useful info
This is some info about the human papilloma virus or HPV.We must understand that all women come in contact with it at least once in their lives.In rare cases the infection caused by the virus can become cancer ( malignant neoplasm ).
Cancer of the cervix and HPV infection - Cancer of the cervix is the long-term consequence of an infection caused by human papillomavirus (HPV). There are over 100 genotypes of HPV. Fifteen of these papillomavirus, known as high risk or oncogenes are associated with the development of cancer of the cervix uteri. The transmission occurs through contact with skin and mucous membranes, most often during sex, with or without penetration. Therefore, the condom, it can limit their contact with the virus, can not provide complete protection.
HPV infection is very common and is acquired mostly in the five years following the first sexual intercourse. In most cases, infection is transient and is eliminated naturally in 1 to 2 years after sexual contamination. But in 10% of cases, the infection persists and can cause abnormalities (lesions) in the cells of the cervix, these lesions can themselves evolve into cancer.
There are several stages of precancerous lesions (called CIN 1, CIN 2, CIN 3), may regress to a cervical normal persist or even develop into cancer of the cervix. This cancer is on average fifteen to twenty years to develop after the persistence and progression of HPV infection in high risk, which leaves a significant window of action for screening and early detection of precancerous lesions and cancer .
Two modes of action exist: The vaccination used preventively, that is to say, before contact with the virus. There are two vaccines currently marketed in France: a bivalent vaccine for protecting said against HPV genotype 16 and 18 and a quadrivalent vaccine protects against HPV types 6,11, 16 and 18.The High Council of Public Health recommends preferably, in its opinion of December 14, 2007, the quadrivalent vaccine.
Screening is essential because of the partial protection of HPV vaccination. It is based on a cervical smear performed every three years for women 25 to 65 years (after the first two normal smears performed one year apart). From 25 years, all young women, whether vaccinated or not, should benefit from screening swabs.
Cancer of the cervix and HPV infection - Cancer of the cervix is the long-term consequence of an infection caused by human papillomavirus (HPV). There are over 100 genotypes of HPV. Fifteen of these papillomavirus, known as high risk or oncogenes are associated with the development of cancer of the cervix uteri. The transmission occurs through contact with skin and mucous membranes, most often during sex, with or without penetration. Therefore, the condom, it can limit their contact with the virus, can not provide complete protection.
HPV infection is very common and is acquired mostly in the five years following the first sexual intercourse. In most cases, infection is transient and is eliminated naturally in 1 to 2 years after sexual contamination. But in 10% of cases, the infection persists and can cause abnormalities (lesions) in the cells of the cervix, these lesions can themselves evolve into cancer.
There are several stages of precancerous lesions (called CIN 1, CIN 2, CIN 3), may regress to a cervical normal persist or even develop into cancer of the cervix. This cancer is on average fifteen to twenty years to develop after the persistence and progression of HPV infection in high risk, which leaves a significant window of action for screening and early detection of precancerous lesions and cancer .
Two modes of action exist: The vaccination used preventively, that is to say, before contact with the virus. There are two vaccines currently marketed in France: a bivalent vaccine for protecting said against HPV genotype 16 and 18 and a quadrivalent vaccine protects against HPV types 6,11, 16 and 18.The High Council of Public Health recommends preferably, in its opinion of December 14, 2007, the quadrivalent vaccine.
The population targeted by this vaccine consists of: girls 14 years before exposure to the risk of HPV infection
girls and young women 15 to 23 years who have not had sex or, later in the year following the start of sexual life. This vaccination does not protect 100% against cancer of the cervix and does not replace the Pap smear screening. These two actions are complementary.
Screening is essential because of the partial protection of HPV vaccination. It is based on a cervical smear performed every three years for women 25 to 65 years (after the first two normal smears performed one year apart). From 25 years, all young women, whether vaccinated or not, should benefit from screening swabs.
If you liked this post, subscribe to our blog by filling your e-mail address below:
Want to add something? Post your comments